Copeptin Levels in Patients With Treatment-Resistant Hypertension Before and 6 Months After Renal Denervation

Am J Hypertens. 2020 Feb 22;33(2):182-189. doi: 10.1093/ajh/hpz155.

Abstract

Background: Copeptin, the C-terminal peptide of provasopressin, is released from the neurohypophysis and reflects the activity of the hormone arginine vasopressin in patients with hypertension. Elevated copeptin levels are associated with increased cardiovascular and all-cause mortality. The aim of this study is to compare copeptin levels in patients with treatment-resistant hypertension (TRH) before and 6 months after renal denervation (RDN).

Methods: Copeptin was measured in 34 patients with TRH and 30 patients with primary hypertension stage 1 or 2 (HT). In addition, copeptin levels were measured in patients with TRH at 6-month follow-up visit after RDN. RDN was performed by an experienced interventionalist applying at least 4 ablations longitudinally and rotationally within the lengths of each renal artery to cover a full 4-quadrant ablation.

Results: In patients with TRH 24-hour ambulatory blood pressure (BP) decreased from 154 ± 15/87 ± 12 mm Hg to 146 ± 13/83 ± 7.9 mm Hg after RDN (systolic: P = 0.001, diastolic: P = 0.034). There was no significant change in copeptin levels in these 34 patients with TRH before vs. 6 months after RDN (median 8.4 [interquartile range 3.6-14] vs. 8.5 [4.5-13] pmol/l, P = 0.334). Patients with TRH had higher copeptin levels (P = 0.024) than patients with HT (24-hour ambulatory BP: 142 ± 11/91 ± 8.3 mm Hg, copeptin: 4.2 [2.8-6.3] pmol/l).

Conclusion: Patients with TRH showed 2-fold higher copeptin levels than patients with HT. RDN did not lead to any change of copeptin levels in patients with TRH 6 months after procedure despite significant fall in BP.

Clinical trial registration: NCT01318395, NCT01687725.

Keywords: blood pressure; copeptin; hypertension; renal denervation; treatment resistance.

MeSH terms

  • Adult
  • Aged
  • Antihypertensive Agents / therapeutic use
  • Biomarkers / blood
  • Blood Pressure* / drug effects
  • Catheter Ablation*
  • Drug Resistance
  • Glycopeptides / blood*
  • Humans
  • Hypertension / blood*
  • Hypertension / diagnosis
  • Hypertension / physiopathology
  • Hypertension / surgery*
  • Kidney / blood supply*
  • Male
  • Middle Aged
  • Renal Artery / innervation*
  • Sympathectomy*
  • Time Factors
  • Treatment Outcome
  • Up-Regulation

Substances

  • Antihypertensive Agents
  • Biomarkers
  • Glycopeptides
  • copeptins

Associated data

  • ClinicalTrials.gov/NCT01318395
  • ClinicalTrials.gov/NCT01687725